{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T07:45:09Z","timestamp":1743666309460},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,22]]},"DOI":"10.7759\/cureus.37992","type":"journal-article","created":{"date-parts":[[2023,4,23]],"date-time":"2023-04-23T01:33:31Z","timestamp":1682213611000},"source":"Crossref","is-referenced-by-count":3,"title":["Dupilumab-Induced Scalp Psoriasis in a Patient With Prurigo Nodularis: A Case Report"],"prefix":"10.7759","author":[{"given":"Khalid","family":"Al Hawsawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amal W","family":"AlDoboke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seham A","family":"Alsulami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghadeer E","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raed F","family":"Alsufi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"DUPIXENT. indications and important safety information. (2022). Accessed: January 13, 2023: https:\/\/www.dupixenthcp.com\/."},{"key":"ref2","article-title":"Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D\u2019Ippolito D","year":"2018","unstructured":"D\u2019Ippolito D, Pisano M. Dupilumab (Dupixent): an interleukin-4 receptor antagonist for atopic dermatitis. P T. 2018, 43:532-5.","journal-title":"P T"},{"key":"ref3","article-title":"Prurigo Nodularis","author":"Mullins TB","year":"2022","unstructured":"Mullins TB, Sharma P, Riley CA, Sonthalia S. Prurigo Nodularis. StatPearls Publishing, Treasure Island, FL; 2022."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64","author":"Langley RG","year":"2005","unstructured":"Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis. 2005, 64:18-23. 10.1136\/ard.2004.033217","journal-title":"Ann Rheum Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000017972","article-title":"Evaluation of topical drug treatment in psoriasis","volume":"197","author":"van de Kerkhof PC","year":"1998","unstructured":"van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998, 197:31-6. 10.1159\/000017972","journal-title":"Dermatology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.08.007","article-title":"Psoriasis: epidemiology","volume":"25","author":"Gudjonsson JE","year":"2007","unstructured":"Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007, 25:535-46. 10.1016\/j.clindermatol.2007.08.007","journal-title":"Clin Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.11.890","article-title":"Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation","volume":"60","author":"Chan CS","year":"2009","unstructured":"Chan CS, Van Voorhees AS, Lebwohl MG, et al.. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009, 60:962-71. 10.1016\/j.jaad.2008.11.890","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15406\/jdc.2020.04.00158","article-title":"A case series of dupilumab-treated atopic dermatitis resulting in new onset psoriasis","volume":"4","author":"Boudreaux L","year":"2020","unstructured":"Boudreaux L. A case series of dupilumab-treated atopic dermatitis resulting in new onset psoriasis. J Dermatology Cosmetol. 2020, 4:83-6. 10.15406\/jdc.2020.04.00158","journal-title":"J Dermatology Cosmetol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.05.014","article-title":"Erythrodermic presentation of psoriasis in a patient treated with dupilumab","volume":"4","author":"Tracey EH","year":"2018","unstructured":"Tracey EH, Elston C, Feasel P, Piliang M, Michael M, Vij A. Erythrodermic presentation of psoriasis in a patient treated with dupilumab. JAAD Case Rep. 2018, 4:708-10. 10.1016\/j.jdcr.2018.05.014","journal-title":"JAAD Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13901","article-title":"Psoriasis induced by dupilumab therapy","volume":"44","author":"Safa G","year":"2019","unstructured":"Safa G, Paumier V. Psoriasis induced by dupilumab therapy. Clin Exp Dermatol. 2019, 44:e49-50. 10.1111\/ced.13901","journal-title":"Clin Exp Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/148198-dupilumab-induced-scalp-psoriasis-in-a-patient-with-prurigo-nodularis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:00:37Z","timestamp":1707508837000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/148198-dupilumab-induced-scalp-psoriasis-in-a-patient-with-prurigo-nodularis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.37992","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,22]]}}}